Celecoxib in Treating Patients With Relapsed Prostate Cancer Following Radiation Therapy or Radical Prostatectomy
Stopped early · Phase 2
Conditions studied: Prostate Cancer
In brief
RATIONALE: Celecoxib may stop the growth of cancer by stopping blood flow to the tumor and by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase II trial to study the effectiveness of celecoxib in treating patients who have relapsed prostate cancer following radiation therapy or radical prostatectomy.
Key facts
- Study ID
- NCT00073970
- Run by
- UNC Lineberger Comprehensive Cancer Center
- People needed
- 37
- Starts
- 2003-04-01
- Expected to finish
- 2006-01-01
- Last updated by the study team
- 2012-05-23
Who can join
Age: 18 and older. Sex: male. Healthy volunteers: not accepted.
Where it is running
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill — Chapel Hill, North Carolina, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.